Pacira Pharmaceuticals traded at $22.70 this Thursday April 2nd, decreasing $0.09 or 0.39 percent since the previous trading session. Looking back, over the last four weeks, Pacira lost 2.71 percent. Over the last 12 months, its price fell by 6.55 percent. Looking ahead, we forecast Pacira Pharmaceuticals to be priced at 22.02 by the end of this quarter and at 20.09 in one year, according to Trading Economics global macro models projections and analysts expectations.
Pacira BioSciences, Inc. is the holding company of Pacira Pharmaceuticals, Inc. The Company is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its other product candidate, the iovera system is a non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature only to targeted nerves. The iovera system is complementary to EXPAREL as a non-opioid therapy that alleviates pain using a non-pharmacological nerve block to disrupt pain signals being transmitted to the brain from the site of injury or surgery.